Neomente
Main Vertical
HealthTech
Website
CEO/FOUNDER
Name and Surname
Ariel Angel Yahia
Linkedin Profile or Bio
Name and Surname
María Gabriela Nielsen
Linkedin Profile or Bio
Number of people on the Staff
6
Legal Form
Simplified Joint Stock Company (SAS)
Year of Founding
2019
Type of Company
Startup
Development Stage
Validation
Province
City of Buenos Aires
City
CABA
Main Business Model
B2B2C
Problem
The problem addressed by the startup Neomente is the difficulty that patients with depression face in finding an effective pharmacological treatment from the start. Currently, many people enter a cycle of trial and error with different antidepressants, which can prolong suffering, increase the risk of adverse effects, and decrease treatment adherence. Neomente seeks to solve this problem through Clinical Decision Support Software (CDSS), which integrates genetic, clinical, and blood biomarker information to help psychiatrists select the most appropriate treatment from the outset. This tool has proven particularly useful in personalizing treatments, reducing failed attempts, and improving response rates, even in cases of resistant depression.
Solutions Offered - Summary
Personalized drug selection using biomarkers.
Solutions Offered - Details
Neomente provides clinical decision support software that integrates genetic, clinical, and blood biomarker data to personalize pharmacological treatment in mental health. It aims to optimize antidepressant selection, reduce trial and error, and improve treatment response, especially in cases of treatment-resistant depression.
Technologies Used
Artificial Intelligence, Big Data or Data Analytics, Cloud, Web Platform
Counterparties of Interest abroad
End Customer
Industries served
Health
International Presence
SPAIN, UNITED STATES
Investment Round:
Seed
Presentation
E-mail
ayahia@neomente.com